Cargando…

Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics

PURPOSE: To describe (1) the clinical profiles and the patterns of use of long-acting injectable (LAI) antipsychotics in patients with schizophrenia at risk of nonadherence with oral antipsychotics, and in those who started treatment with LAI antipsychotics, (2) health care resource utilization and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernardo, Miguel, San, Luis, Olivares, José M, Dilla, Tatiana, Polavieja, Pepa, Gilaberte, Inmaculada, Álvarez, María, Ciudad, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259075/ https://www.ncbi.nlm.nih.gov/pubmed/22259237 http://dx.doi.org/10.2147/PPA.S26253

Ejemplares similares

Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia
por: Dilla, Tatiana, et al.
Publicado: (2013)

Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis
por: Romera, Irene, et al.
Publicado: (2013)

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review
por: Zhornitsky, Simon, et al.
Publicado: (2012)

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
por: Haddad, Peter M, et al.
Publicado: (2014)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
por: Olivares, Jose Manuel, et al.
Publicado: (2013)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand
por: Suttajit, Sirijit, et al.
Publicado: (2010)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10
por: Tatini, Lorenzo, et al.
Publicado: (2021)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada
por: Lammers, Laura, et al.
Publicado: (2013)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Monitoring of antipsychotic plasma levels in the assessment of poor response and nonadherence to antipsychotics in delusional disorder
por: González-Rodríguez, A., et al.
Publicado: (2021)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
por: Baeza, Inmaculada, et al.
Publicado: (2023)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
por: Stevens, Georgia L., et al.
Publicado: (2015)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
por: Hýža, Martin, et al.
Publicado: (2021)

Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study
por: Romera, Irene, et al.
Publicado: (2011)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
por: Viala, Annie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_temvshlu61nm0o68fn1lkl9158